probenecid has been researched along with Kidney Diseases in 71 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " These initial studies demonstrate that tienilic acid is safe and effective in the treatment of mild to moderate essential hypertension, salt and water retention states, including oedema associated with congestive cardiac failure or mild to moderate renal dysfunction, and in the management of elevated serum uric acid levels associated with gout." | 5.04 | Safety of tienilic acid. ( Beg, MA; Ragland, R, 1979) |
| "Gout is a clinical syndrome encompassing a group of metabolic diseases that are all characterized by abnormal uric acid metabolism." | 4.77 | Hyperuricemia and gout. ( German, DC; Holmes, EW, 1986) |
| "62 mg/kg) both without and with oral probenecid in 9 transplant patients with persistent BK viremia without nephropathy in a crossover design." | 3.79 | Pharmacokinetics of low-dose cidofovir in kidney transplant recipients with BK virus infection. ( Gao, Y; Momper, JD; Randhawa, PS; Schonder, KS; Shapiro, R; Venkataramanan, R; Zhao, Y, 2013) |
| " Probenecid pretreatment led to a reduction in Tris-BP and Bis-BP tubular necrosis, these effects may be related to inhibition of Bis-BP uptake in the kidney." | 3.67 | Nephrotoxicity of selectively deuterated and methylated analogues of Tris-BP and Bis-BP in the rat. ( Dahl, JE; Dybing, E; Nelson, SD; Omichinski, JG; Søderlund, EJ, 1988) |
| "Hematuria and eosinophilia developed in two patients being treated for bacterial endocarditis with 20 or 24 gm/day of cephalexin given orally together with probenecid (Benemid)." | 3.65 | Cephalexin-related nephropathy. ( Kieff, E; Verma, S, 1975) |
| " The objective of this study was to use physiologically based pharmacokinetic (PBPK) modelling to evaluate the effects of patient factors on kidney transporters." | 2.50 | Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. ( Berglund, EG; de L T Vieira, M; Giacomini, KM; Hsu, V; Huang, SM; Nordmark, A; Zhang, L; Zhao, P; Zheng, JH, 2014) |
| " In adults, the Cmax following administration of the suspension or solution formulations is higher than that achieved following administration of the capsule formulation, and the time to reach peak concentration (Tmax) is increased when loracarbef is administered as a capsule; however, the area under the curve, plasma half-life, and percentage of oral dose excreted in the urine are comparable among all formulations." | 2.38 | Pharmacokinetic profile of loracarbef. ( DeSante, KA; Zeckel, ML, 1992) |
| "Probenecid treatment significantly reduced hippuran clearance (P < 0." | 1.31 | Mapping of local renal blood flow with PET and H(2)(15)O. ( Alpert, NM; Babich, JW; Correia, DJ; Fischman, AJ; Littman, BH; Rabito, CA; Rubin, NT; Rubin, RH; Tompkins, RG, 2002) |
| "Cephaloridine (CER) has been used to elucidate the mechanisms of cephalosporin antibiotic-induced nephrotoxicity." | 1.30 | Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity. ( Endou, H; Hosoyamada, M; Kanai, Y; Sekine, T; Takeda, M; Tojo, A, 1999) |
| "Probenecid pretreatment promoted an elevation in the urinary 16-hr excretion of APAP and a diminution in the plasma levels attained by APAP." | 1.30 | Probenecid protects against In vivo acetaminophen-induced nephrotoxicity in male Wistar rats. ( Elías, MM; Monasterolo, LA; Trumper, L, 1998) |
| "Hematuria was seen in 7 out of the 16 patients (44%), all of whom were females (58%)." | 1.30 | Hematuria in patients with renal hypouricemia. ( Hamada, N; Hiroe, K; Hisatome, I; Kato, T; Kinugawa, T; Manabe, I; Ogino, K; Ohtahara, A; Sato, R; Shigemasa, C; Shimoyama, M; Takeda, A; Tanaka, Y; Tsuboi, M; Yamamoto, Y; Yoshida, A, 1998) |
| " We have recently reported that a glutathione conjugate of PAP, 4-amino-3-S-glutathionylphenol, is more toxic to the kidney than the parent compound itself." | 1.29 | Effect of ascorbic acid, acivicin and probenecid on the nephrotoxicity of 4-aminophenol in the Fischer 344 rat. ( Foster, JR; Fowler, LM; Lock, EA, 1993) |
| " Early studies by several investigators demonstrated that similar compounds such as alpha, beta-unsaturated aldehyde-cysteine adducts have toxic (carcinostatic) activity against Ehrlich ascites tumor cells implanted in mice." | 1.28 | Nephrotoxicity of the 1:1 acrolein-glutathione adduct in the rat. ( Horvath, JJ; Witmer, CM; Witz, G, 1992) |
| "Probenecid was found to inhibit both kidney binding and toxicity of DCVC." | 1.28 | Dichlorovinyl cysteine (DCVC) in the mouse kidney: tissue-binding and toxicity after glutathione depletion and probenecid treatment. ( Bakke, JE; Brandt, I; Darnerud, PO; Feil, VJ, 1989) |
| " The results indicate that reduced renal mass increased the plasma half-life for cefotaxime as well as increasing its diffusion into tissue." | 1.27 | Pharmacokinetics of cefotaxime and probenecid in sheep with normal and reduced renal function. ( Bourne, DW; Cao, GR; English, PB; Filippich, LJ; Guerrini, VH, 1984) |
| " This article attempts to critically review these studies under seven different sections: furosemide pharmacokinetics in normal volunteers, furosemide pharmacokinetics in patients with decreased renal function, furosemide pharmacokinetics in patients with congestive heart failure, furosemide metabolism and assay methods, furosemide bioavailability, dose-response relationships, and the role of inhibitors and mediators on furosemide effects." | 1.26 | Pharmacokinetics/pharmacodynamics of furosemide in man: a review. ( Benet, LZ, 1979) |
| "Uric acid excretion was only slightly affected by pyrazinamide, a drug which suppresses renal tubular uric acid secretion, and by probenecid, a drug which inhibits tubular uric acid reabsorption." | 1.26 | Familial hypouricemia due to isolated renal tubular defect. Attenuated response of uric acid clearance to probenecid and pyrazinamide. ( Benjamin, D; de Vries, A; Pinkhas, J; Sperling, O; Weinberger, A, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 49 (69.01) | 18.7374 |
| 1990's | 14 (19.72) | 18.2507 |
| 2000's | 6 (8.45) | 29.6817 |
| 2010's | 2 (2.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takeda, M | 3 |
| Tojo, A | 2 |
| Sekine, T | 2 |
| Hosoyamada, M | 2 |
| Kanai, Y | 1 |
| Endou, H | 3 |
| Ichida, K | 1 |
| Kimura, H | 1 |
| Utsunomiya, Y | 1 |
| Hosoya, T | 1 |
| Hsu, V | 1 |
| de L T Vieira, M | 1 |
| Zhao, P | 1 |
| Zhang, L | 1 |
| Zheng, JH | 1 |
| Nordmark, A | 1 |
| Berglund, EG | 1 |
| Giacomini, KM | 1 |
| Huang, SM | 1 |
| Bakhiya, N | 1 |
| Arlt, VM | 1 |
| Bahn, A | 1 |
| Burckhardt, G | 1 |
| Phillips, DH | 1 |
| Glatt, H | 1 |
| Momper, JD | 1 |
| Zhao, Y | 1 |
| Shapiro, R | 1 |
| Schonder, KS | 1 |
| Gao, Y | 1 |
| Randhawa, PS | 1 |
| Venkataramanan, R | 1 |
| Yamanaka, H | 1 |
| BRONSKY, D | 1 |
| DUBIN, A | 1 |
| KUSHNER, DS | 1 |
| PHILLIPS, RW | 1 |
| HAAGENSEN, NR | 1 |
| NIELSEN, B | 1 |
| BATT, RE | 1 |
| CIRKSENA, WJ | 1 |
| LEBHERZ, TB | 1 |
| STERN, FH | 1 |
| TALBOT, FJ | 1 |
| TREADWELL, B | 1 |
| REAH, TG | 1 |
| EPSTEIN, FH | 1 |
| PIGEON, G | 1 |
| Smith, H | 1 |
| Lerner, PI | 1 |
| Weinstein, L | 1 |
| Guerrini, VH | 1 |
| Filippich, LJ | 1 |
| English, PB | 1 |
| Cao, GR | 1 |
| Bourne, DW | 1 |
| Schlech, WF | 1 |
| Gelfand, M | 1 |
| Alper, B | 1 |
| Kaiser, AB | 1 |
| Saito, A | 1 |
| Faed, EM | 1 |
| Shimizu, K | 1 |
| Daley-Yates, PT | 1 |
| McBrien, DC | 1 |
| Lang, F | 1 |
| Greger, R | 1 |
| Oberleithner, H | 1 |
| Griss, E | 1 |
| Lang, K | 1 |
| Pastner, D | 1 |
| Dittrich, P | 1 |
| Deetjen, P | 1 |
| Muñoz Sanz, A | 1 |
| García Puig, J | 1 |
| Mateos, F | 1 |
| Barbado, FJ | 1 |
| Berndt, WO | 1 |
| Hayes, AW | 1 |
| Zawadzki, J | 1 |
| Grenda, R | 1 |
| Januszewicz, P | 1 |
| Hisatome, I | 2 |
| Tanaka, Y | 2 |
| Kotake, H | 1 |
| Kosaka, H | 1 |
| Hirata, N | 1 |
| Fujimoto, Y | 1 |
| Yoshida, A | 2 |
| Shigemasa, C | 2 |
| Mashiba, H | 1 |
| Sato, R | 2 |
| Fowler, LM | 1 |
| Foster, JR | 1 |
| Lock, EA | 2 |
| Trumper, L | 1 |
| Monasterolo, LA | 1 |
| Elías, MM | 1 |
| Ogino, K | 1 |
| Shimoyama, M | 1 |
| Hiroe, K | 1 |
| Tsuboi, M | 1 |
| Yamamoto, Y | 1 |
| Hamada, N | 1 |
| Kato, T | 1 |
| Manabe, I | 1 |
| Kinugawa, T | 1 |
| Ohtahara, A | 1 |
| Takeda, A | 1 |
| Ishmael, J | 1 |
| Gröbner, W | 1 |
| Walter-Sack, I | 1 |
| Alpert, NM | 1 |
| Rabito, CA | 1 |
| Correia, DJ | 1 |
| Babich, JW | 1 |
| Littman, BH | 1 |
| Tompkins, RG | 1 |
| Rubin, NT | 1 |
| Rubin, RH | 1 |
| Fischman, AJ | 1 |
| Enomoto, A | 1 |
| Cha, SH | 1 |
| Khamdang, S | 1 |
| Takayama, F | 1 |
| Aoyama, I | 1 |
| Nakamura, S | 1 |
| Niwa, T | 1 |
| Schrogie, JJ | 1 |
| Davies, RO | 1 |
| Yeh, KC | 1 |
| Rogers, D | 1 |
| Holmes, GI | 1 |
| Skeggs, H | 1 |
| Martin, CM | 1 |
| Boss, GR | 1 |
| Seegmiller, JE | 1 |
| Campanacci, L | 1 |
| Beg, MA | 1 |
| Ragland, R | 1 |
| Benet, LZ | 1 |
| Frank, M | 1 |
| Many, M | 1 |
| Sperling, O | 2 |
| Kawenoki-Minc, E | 1 |
| Eyman, E | 1 |
| Abgarowicz, T | 1 |
| Brzozowska-Jurkowska, M | 1 |
| Weryńska-Przybylska, J | 1 |
| Benjamin, D | 1 |
| Weinberger, A | 1 |
| Pinkhas, J | 1 |
| de Vries, A | 1 |
| Verma, S | 1 |
| Kieff, E | 1 |
| Raab, WP | 1 |
| Moerth, CM | 1 |
| Horvath, JJ | 1 |
| Witmer, CM | 1 |
| Witz, G | 1 |
| Kawachi, M | 2 |
| Kono, N | 3 |
| Kiyokawa, H | 2 |
| Mineo, I | 2 |
| Nakajima, H | 3 |
| Shimizu, T | 2 |
| Yorifuji, S | 2 |
| Kuwajima, M | 2 |
| Tarui, S | 2 |
| DeSante, KA | 1 |
| Zeckel, ML | 1 |
| Ono, A | 1 |
| Nishimura, T | 1 |
| Monks, TJ | 1 |
| Jones, TW | 1 |
| Hill, BA | 1 |
| Lau, SS | 1 |
| Shichiri, M | 2 |
| Itoh, H | 1 |
| Iwamoto, H | 2 |
| Hirata, Y | 1 |
| Marumo, F | 1 |
| Rauer, S | 1 |
| Schollmeyer, P | 1 |
| Darnerud, PO | 1 |
| Brandt, I | 1 |
| Feil, VJ | 1 |
| Bakke, JE | 1 |
| Ban, M | 1 |
| de Céaurriz, J | 1 |
| Søderlund, EJ | 1 |
| Omichinski, JG | 1 |
| Dahl, JE | 1 |
| Nelson, SD | 1 |
| Dybing, E | 1 |
| Maeda, M | 1 |
| Kanayama, M | 1 |
| Shiigai, T | 1 |
| German, DC | 1 |
| Holmes, EW | 1 |
| Mihatsch, MJ | 1 |
| Ryffel, B | 1 |
| Hermle, M | 1 |
| Brunner, FP | 1 |
| Thiel, G | 1 |
| Gomi, M | 1 |
| Iida, S | 1 |
| Moriwaki, K | 1 |
| Richards, DM | 1 |
| Heel, RC | 1 |
| Smetana, SS | 1 |
| Bar-Khayim, Y | 1 |
| Linsell, WD | 1 |
| Pines, A | 1 |
| Hayden, JW | 1 |
| Westenfelder, SR | 1 |
| Naber, KG | 1 |
| Madsen, PO | 1 |
| Petitpierre, B | 2 |
| Perrin, L | 2 |
| Rudhardt, M | 2 |
| Herrera, A | 1 |
| Fabre, J | 2 |
| Klinenberg, JR | 1 |
| Bluestone, R | 1 |
| Campion, D | 1 |
| Whitehouse, M | 1 |
| Simkin, PA | 1 |
| Skeith, MD | 1 |
| Healey, LA | 1 |
| Gutman, AB | 1 |
| Klotz, H | 1 |
| Prohaska, E | 1 |
| Salmhofer, H | 1 |
| Schmid, L | 1 |
| Riccitelli, ML | 1 |
| Holländer, E | 1 |
| Schwarczmann, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)[NCT00000142] | Phase 2/Phase 3 | 64 participants (Actual) | Interventional | 1994-04-30 | Completed | ||
| HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol[NCT00000799] | 100 participants | Interventional | Completed | ||||
| Kidney Transplantation and Renal and Myocardial Perfusion[NCT02960802] | 60 participants (Anticipated) | Interventional | 2017-01-01 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000142)
Timeframe: All patients enrolled will be followed until a common study closing date
| Intervention | participants (Number) | ||
|---|---|---|---|
| mortality | progression | va loss of 15 letters | |
| Cidofovir (High Dose) | 3 | 5 | 2 |
| Cidofovir (Low Dose) | 7 | 17 | 6 |
| Treatment Deferral | 6 | 20 | 4 |
8 reviews available for probenecid and Kidney Diseases
| Article | Year |
|---|---|
Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations.
Topics: Animals; Computer Simulation; Humans; Kidney; Kidney Diseases; Membrane Transport Proteins; Models, | 2014 |
[Drug therapy for idiopathic hyperuricemia--introduction, dose, and side effects].
Topics: Allopurinol; Arteriosclerosis; Benzbromarone; Enzyme Inhibitors; Gout; Humans; Hyperuricemia; Kidney | 2003 |
Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs.
Topics: Acylation; Animals; Bile; Glucuronates; Humans; Hydrolysis; Kidney Diseases; Kinetics; Macromolecula | 1984 |
Bioavailability and pharmacokinetics of cefoxitin sodium.
Topics: Absorption; Animals; Biological Availability; Cefoxitin; Cephalosporins; Chemical Phenomena; Chemist | 1978 |
Hyperuricemia and gout. Classification, complications and management.
Topics: Acute Disease; Allopurinol; Arthritis; Aspirin; Colchicine; Coronary Disease; Diuretics; Gout; Human | 1979 |
Pharmacokinetic profile of loracarbef.
Topics: Adult; Age Factors; Biological Availability; Cephalosporins; Child; Clinical Trials as Topic; Food; | 1992 |
Hyperuricemia and gout.
Topics: Acute Disease; Adult; Allopurinol; Anti-Inflammatory Agents; Arthritis; Arthrography; Calcinosis; Ch | 1986 |
Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Biotransformation; Blood Coagulation; Cefotax | 1985 |
4 trials available for probenecid and Kidney Diseases
59 other studies available for probenecid and Kidney Diseases
| Article | Year |
|---|---|
Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity.
Topics: Animals; Anion Transport Proteins; Anticholesteremic Agents; Antigens, Polyomavirus Transforming; Bi | 1999 |
Urate transport via human PAH transporter hOAT1 and its gene structure.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Biological Transport; Blotting, Western; Car | 2003 |
Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy.
Topics: Animals; Aristolochic Acids; Cells, Cultured; DNA Adducts; Extracellular Space; Female; Humans; Kidn | 2009 |
Pharmacokinetics of low-dose cidofovir in kidney transplant recipients with BK virus infection.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Antiviral Agents; Area Under Curve; BK Virus; Cidofovir; Cross | 2013 |
Diuretic action of benemid; its effect upon the urinary excretion of sodium, chloride, potassium and water in edematous subjects.
Topics: Diuresis; Diuretics; Edema; Electrolytes; Heart Failure; Humans; Kidney Diseases; Potassium; Probene | 1955 |
Reversal of renal insufficiency in gout; report of a case treated with probenecid (benemid).
Topics: Gout; Humans; Kidney Diseases; Probenecid; Renal Insufficiency | 1955 |
The effect of probenecid on renal excretion and plasma level of uric acid in patients with renal insufficiency.
Topics: Humans; Kidney; Kidney Diseases; Metabolic Diseases; Probenecid; Renal Elimination; Renal Insufficie | 1961 |
GOUT AND SALT-WASTING RENAL DISEASE DURING PREGNANCY; DIAGNOSIS, MANAGEMENT, AND FOLLOW-UP.
Topics: Blood Chemical Analysis; Colchicine; Diet Therapy; Diet, Sodium-Restricted; Female; Follow-Up Studie | 1963 |
GOUT. A FIVE-YEAR REVIEW.
Topics: Adrenocorticotropic Hormone; Arthritis; Aspirin; Codeine; Colchicine; Diagnosis, Differential; Diet; | 1963 |
PROPRIETARY DRUG ABUSE; REPORT OF A PROBABLE CASE OF BURNETT'S SYNDROME DUE TO EXCESSIVE INGESTION OF AN OVER-THE-COUNTER REMEDY, TUMS.
Topics: Alkalosis; Anemia; Antacids; Blood Transfusion; Calcinosis; Carbonates; Colchicine; Humans; Hypercal | 1964 |
THE TREATMENT OF GOUT.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Colchicine; Diet; Diet Therapy; Dr | 1964 |
GOUT.
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Colchicine; Diagnosis, Differential; Diet; Diet | 1964 |
EXPERIMENTAL URATE NEROPATHY: STUDIES OF THE DISTRIBUTION OF URATE IN RENAL TISSUE.
Topics: Blood Chemical Analysis; Dogs; Histocytochemistry; Kidney Diseases; Kidney Function Tests; Mannitol; | 1964 |
Neurotoxicity and "massive" intravenous therapy with penicillin. A study of possible predisposing factors.
Topics: Adolescent; Adult; Aged; Central Nervous System; Central Nervous System Diseases; Child; Child, Pres | 1967 |
Pharmacokinetics of cefotaxime and probenecid in sheep with normal and reduced renal function.
Topics: Animals; Cefotaxime; Female; Glomerular Filtration Rate; Hydrogen-Ion Concentration; Injections, Int | 1984 |
Medical management of visceral actinomycosis.
Topics: Abscess; Actinomycosis; Adult; Diagnosis, Differential; Drug Therapy, Combination; Female; Gingival | 1983 |
Studies on absorption, distribution, metabolism and excretion of ceftazidime in Japan.
Topics: Adult; Alcohol Deterrents; Bile; Cefoperazone; Ceftazidime; Cephalosporins; Dose-Response Relationsh | 1983 |
Cefoperazone: absorption, excretion, distribution, and metabolism.
Topics: Adult; Animals; Ascitic Fluid; Bile; Cefoperazone; Cephalosporins; Dogs; Female; Haplorhini; Humans; | 1980 |
Enhancement of cisplatin nephrotoxicity by probenecid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Female; Kidney D | 1984 |
[Renal physiopathology of uric acid. Pharmacologic study].
Topics: Humans; Kidney Diseases; Kidney Tubules; Probenecid; Pyrazinamide; Uric Acid; Uricosuric Agents | 1982 |
The effect of probenecid on citrinin-induced nephrotoxicity.
Topics: Animals; Benzopyrans; Chromatography, High Pressure Liquid; Citrinin; In Vitro Techniques; Kidney; K | 1982 |
Effect of nifedipine on tubular handling of uric acid in transplanted kidney on cyclosporine A treatment.
Topics: Adolescent; Adult; Child; Creatinine; Cyclosporine; Delayed-Action Preparations; Drug Therapy, Combi | 1995 |
Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)-citrate.
Topics: Benzbromarone; Citrates; Creatinine; Female; Humans; Hydrogen-Ion Concentration; Kidney Diseases; Ki | 1993 |
Effect of ascorbic acid, acivicin and probenecid on the nephrotoxicity of 4-aminophenol in the Fischer 344 rat.
Topics: Aminophenols; Animals; Antimetabolites; Ascorbic Acid; Isoxazoles; Kidney; Kidney Diseases; Kidney F | 1993 |
Probenecid protects against In vivo acetaminophen-induced nephrotoxicity in male Wistar rats.
Topics: Acetaminophen; Acute Disease; Animals; Biological Transport; Creatinine; Diuresis; Glomerular Filtra | 1998 |
Hematuria in patients with renal hypouricemia.
Topics: Adult; Aged; Aged, 80 and over; Benzbromarone; Creatinine; Female; Hematuria; Humans; Kidney Disease | 1998 |
The nephrotoxicity and hepatotoxicity of 1,1,2,2-tetrafluoroethyl-L-cysteine in the rat.
Topics: Acetylcysteine; Aminooxyacetic Acid; Animals; Butadienes; Cysteine; Dose-Response Relationship, Drug | 1998 |
[Hyperuricemia and gout--treatment].
Topics: Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Colchicine; Drug | 2002 |
Mapping of local renal blood flow with PET and H(2)(15)O.
Topics: Humans; Iodine Radioisotopes; Iodohippuric Acid; Kidney Cortex; Kidney Diseases; Kidney Function Tes | 2002 |
Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity.
Topics: Animals; Anions; Biological Transport; Cell Line; Cell Survival; Chromatography, High Pressure Liqui | 2002 |
[The gouty kidney: physiopathology, clinical aspects and therapy].
Topics: Benzofurans; Gout; Humans; Kidney Diseases; Probenecid | 1977 |
Pharmacokinetics/pharmacodynamics of furosemide in man: a review.
Topics: Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Furosemide; Heart Fail | 1979 |
Familial renal hypouricaemia: two additional cases with uric acid lithiasis.
Topics: Adult; Calcium; Humans; Jews; Kidney Calculi; Kidney Diseases; Male; Pedigree; Probenecid; Pyrazinam | 1979 |
[Various aspects of nephropathy in gout].
Topics: Adult; Age Factors; Aged; Amyloidosis; Glomerular Filtration Rate; Gout; Humans; Hypertension, Renal | 1978 |
Familial hypouricemia due to isolated renal tubular defect. Attenuated response of uric acid clearance to probenecid and pyrazinamide.
Topics: Adult; Female; Humans; Kidney Diseases; Kidney Function Tests; Kidney Tubules, Proximal; Probenecid; | 1977 |
Cephalexin-related nephropathy.
Topics: Administration, Oral; Adult; Cephalexin; Drug Hypersensitivity; Endocarditis; Eosinophilia; Hematuri | 1975 |
Probenecid and the rat kidney: investigations by renal enzyme excretion technique.
Topics: Animals; Fructose-Bisphosphate Aldolase; Kidney Diseases; Kidney Tubules; Male; Muramidase; Probenec | 1976 |
Nephrotoxicity of the 1:1 acrolein-glutathione adduct in the rat.
Topics: Acrolein; Animals; Disulfiram; Glutathione; Isoxazoles; Kidney Diseases; Kidney Tubules, Proximal; M | 1992 |
Decreased renal clearance of xanthine and hypoxanthine in a patient with renal hypouricemia: a new defect in renal handling of purines.
Topics: Humans; Hypoxanthine; Hypoxanthines; Kidney Diseases; Male; Metabolic Clearance Rate; Middle Aged; P | 1992 |
Renal hypouricemia associated with hyperoxypurinemia due to decreased renal excretion of oxypurines: a new defect in renal purine transport.
Topics: Diet; Humans; Hypoxanthine; Hypoxanthines; Kidney Diseases; Kidney Tubules; Kinetics; Male; Middle A | 1991 |
Nephrotoxicity of 2-bromo-(cystein-S-yl) hydroquinone and 2-bromo-(N-acetyl-L-cystein-S-yl) hydroquinone thioethers.
Topics: Aminooxyacetic Acid; Animals; Cysteine; Hydroquinones; Kidney; Kidney Diseases; Male; Necrosis; Prob | 1991 |
Renal tubular hypouricemia: evidence for defect of both secretion and reabsorption.
Topics: Aged; Aspirin; Creatinine; Furosemide; Humans; Kidney Diseases; Kidney Function Tests; Kidney Tubule | 1990 |
Evaluation of urate renal handling in humans.
Topics: Adult; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Male; Probenecid; Pyrazinamide; Uric | 1989 |
Dichlorovinyl cysteine (DCVC) in the mouse kidney: tissue-binding and toxicity after glutathione depletion and probenecid treatment.
Topics: Animals; Autoradiography; Cysteine; Female; Glutathione; Kidney; Kidney Diseases; Kidney Tubules; Mi | 1989 |
Probenecid-induced protection against acute hexachloro-1,3-butadiene and methyl mercury toxicity to the mouse kidney.
Topics: Animals; Butadienes; Kidney Diseases; Male; Methylmercury Compounds; Mice; Probenecid | 1988 |
Nephrotoxicity of selectively deuterated and methylated analogues of Tris-BP and Bis-BP in the rat.
Topics: Animals; Blood Urea Nitrogen; Body Weight; Creatinine; Gas Chromatography-Mass Spectrometry; Glutath | 1988 |
Hypouricemia due to subtotal defect in the urate transport.
Topics: Adult; Biological Transport; Female; Humans; Kidney Diseases; Kidney Tubules; Probenecid; Pyrazinami | 1987 |
Morphology of cyclosporine nephrotoxicity in the rat.
Topics: Animals; Cyclosporins; Female; Glucose; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Male | 1986 |
Familial renal hypouricemia with intact reabsorption of uric acid.
Topics: Adult; Female; Humans; Kidney Diseases; Kidney Tubules; Male; Middle Aged; Probenecid; Pyrazinamide; | 1987 |
Hypouricemia due to renal tubular defect. A study with the probenecid-pyrazinamide test.
Topics: Adult; Calcium; Creatinine; Female; Humans; Kidney Diseases; Kidney Function Tests; Kidney Tubules; | 1985 |
Hyaline cast formation in patients treated with cephaloridine.
Topics: Albuminuria; Ampicillin; Bronchitis; Cephaloridine; Erythrocytes; Humans; Hyalin; Kidney; Kidney Dis | 1967 |
Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.
Topics: Acenocoumarol; Allopurinol; Chloramphenicol; Chlorpropamide; Clofibrate; Glomerular Filtration Rate; | 1972 |
The binding of urate to plasma proteins.
Topics: Allopurinol; Aspirin; Binding Sites; Blood Proteins; Colchicine; Dialysis; Evaluation Studies as Top | 1974 |
Suppression of uric acid secretion in a patient with renal hypouricemia.
Topics: Circadian Rhythm; Creatinine; Female; Humans; Kidney Diseases; Middle Aged; Probenecid; Purine-Pyrim | 1974 |
Medical management of gout.
Topics: Adult; Allopurinol; Colchicine; Diet Therapy; Female; Gout; Humans; Kidney Diseases; Male; Middle Ag | 1972 |
[Behavior of chlorpropamide in nephropathies in the presence of associated drugs].
Topics: Allopurinol; Chloramphenicol; Chlorpropamide; Chromium Isotopes; Humans; Kidney Diseases; Probenecid | 1972 |
[Gout from the view of a special hospital for rheumatic patients].
Topics: Acute Disease; Adolescent; Adult; Aged; Austria; Child; Cholesterol; Colchicine; Colic; Diabetes Com | 1971 |
Etiology and treatment of gout--modern concepts.
Topics: Allopurinol; Colchicine; Crystallization; Diagnosis, Differential; Diet Therapy; Gout; Humans; Indom | 1968 |
[Gout in advanced age].
Topics: Age Factors; Aged; Allopurinol; Bone and Bones; Cardiovascular Diseases; Colchicine; Female; Gout; H | 1968 |